So what? Does the test lead to improved health outcomes?

Neurology

Volumn 77, Issue 17, 2011, Pages 1586-1587

  Trevathan, Edwin ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 82955167982     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182395d81     Document Type: Editorial

References (6)

1. US Department of Health and Human Services. The Healthcare Law and You. Available at: http://www.healthcare.gov/law/index.html. Accessed September 20, 2011.
2. Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: genetic and metabolic testing in children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011; 77:1629-1635.
3. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86: 749-764.
4. Nelson LP, Getzin A, Graham D, et al. Unmet dental needs and barriers to care for children with significant special healthcare needs. Pediatr Dent 2011;33:29-36.
5. Centers for Disease Control and Prevention. Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection: April-August, 2009. MMWR 2009;58:941-947.
6. Insurance Coverage for Autism: National Conference of State Legislatures, May, 2011. Available at: http:// www.ncsl.org/?tabid-18246. Accessed September 20, 2011.